National Institute of Allergy and Infectious Diseases 2R44AI177051-02A1

High-performance antibiofilm central venous catheters for prevention of central line associated bloodstream infections

Award to ACATECHOL, INC. for developing advanced antibiofilm central venous catheters to prevent bloodstream infections, aiming to reduce infection rates by over 80% and improve patient outcomes.

Description

This project aims to develop a novel anti-infective central venous catheter (CVC) with durable biofilm repellency and prolonged antimicrobial activity to significantly reduce infection rates associated with central line associated bloodstream infections (CLABSIs). The innovation involves creating a double-network scaffold with multiple anti-infective mechanisms, manufacturing prototype CVCs, demonstrating superior long-term biofilm reduction, and validating efficacy and safety in animal models. Expected outcomes include scalable manufacturing protocols, improved biofilm efficacy, and a greater than 80% reduction in infection rates, leading to regulatory approval and market entry. The project has the potential to save over 100,000 lives annually and reduce costs by over $12.5 billion.

View original record